0A9G Stock Chart & Stats
$0.28
>-$0.01(-0.87%)
At close: 4:00 PM EDT
$0.28
>-$0.01(-0.87%)
Day’s Range― - ―
52-Week Range$0.22 - $2.36
Previous CloseN/A
Volume14.20K
Average Volume (3M)213.92K
Market Cap
$39.90M
Enterprise Value$21.97
Total Cash (Recent Filing)$30.12M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 17, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,690,980
10 Day Avg. Volume24,571
30 Day Avg. Volume213,917
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside971.43% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$1.77M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageDebt is only about $1.0M against $28.7M of equity, limiting interest and solvency pressure. This conservative leverage gives Mereo more flexibility than a heavily indebted biotech to allocate capital toward clinical programs and partnerships.
Partnering EconomicsThe Sentynl agreement adds a non-refundable option fee and potential $40M upfront and R&D payments, $435M in milestones, and tiered royalties. These contingent economics could fund development while reducing the need to build a full commercial infrastructure alone.
Capital-Light Rare Disease StrategyMereo's focus on oncology and rare-disease therapies for unmet needs, combined with licensing and collaboration-based monetization, creates potential to capture value from differentiated candidates without relying solely on near-term product sales. Success remains development-dependent.
Bears Say
Weak Current ProfitabilityTTM revenue is effectively zero, down 100%, while TTM net loss is about $28.1M and operating profit is deeply negative. This weak current earnings base makes the company dependent on future clinical or partnering outcomes rather than established commercial demand.
Persistent Cash BurnTTM operating cash flow of roughly -$25.3M and free cash flow of -$25.0M show that operations are not self-funding. Persistent cash burn raises ongoing financing needs and can constrain the pace of clinical investment if external capital or partner payments are delayed.
Nasdaq Compliance RiskThe Nasdaq extension preserves the listing temporarily but leaves a defined compliance deadline and potential delisting risk. Losing the listing could reduce market visibility and complicate access to investors and financing, adding pressure while the company funds development.
Mereo Biopharma Group Plc News
0A9G FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest share price was $0.22 and its highest was $2.36 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $39.90M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 72 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.02.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,690,980 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went up 22.968%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in GB:0A9G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
0A9G Stock 12 Month Forecast
Average Price Target
$3.00
▲(971.43% Upside)